Surgery After Chemotherapy and Immunotherapy for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This study follows patients with advanced non-small cell lung cancer (NSCLC) who receive combination chemotherapy and immunotherapy before surgery. Researchers will track how well surgery works after this pre-surgical treatment and compare different surgical approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with non-small cell lung cancer (NSCLC) that is stage IIB or III without spread to distant sites
- Planned to receive chemotherapy combined with an immunotherapy drug (PD-1 or PD-L1 inhibitor) before surgery with curative intent
- Completed at least one cycle of the chemotherapy-immunotherapy combination
- Had chest imaging (CT scan, with or without PET scan) before treatment started and again 2-6 weeks after the last treatment dose
- Planning to have surgery 2-10 weeks after completing pre-surgical treatment
- Good overall health status (ECOG performance score 0-2) and able to complete 90 days of follow-up after surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining immunotherapy with chemotherapy before robot-assisted lung surgery improves outcomes for patients with stage II–III non-small cell lung cancer. The goal is to shrink the tumor before surgery and then remove it completely using minimally invasive robotic techniques.
This trial tests a new combination of radiation, immunotherapy, and chemotherapy given before surgery for stage II or III lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This study tests whether adding radiotherapy (high-energy beams) to an immunotherapy drug (which helps the immune system fight cancer) works better than immunotherapy alone for people with non-small cell lung cancer that has spread to lymph nodes after surgery. It is for people who already had chemotherapy and immunotherapy before surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.